Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Aditxt Completes Third Parent Equity Investment Under Amended And Restated Merger Agreement With Evofem
Aditxt (NASDAQ: ADTX) has completed the Third Parent Equity Investment in Evofem Biosciences (OTCQB: EVFM) under their Amended and Restated Merger Agreement. Aditxt purchased 460 shares of Evofem Series F-1 Convertible Preferred Stock for $460,000, bringing their total investment to $1.72 million. Aditxt plans to complete the Fourth Parent Equity Investment of $2.28 millionby October 31, 2024.
Evofem has expanded from a single-product company to offering diversified solutions in women's health, including Phexxi (contraceptive gel) and SOLOSEC(antibiotic). They are preparing to launch the Mitomic Endometriosis Test in mid-2025 and have signed a licensing agreement with Pharma 1 Drug Store to bring Phexxi to the Gulf Cooperation Council region.
Aditxt aims to accelerate innovative health companies through its business platform, which includes subsidiaries Adimune (immune health) and Pearsanta (precision health). Both companies believe the merger will strengthen Evofem's ability to expand access to women's health products globally.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
4
1
+0
Translate
Report
3630 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2467Followers
    107Following
    26KVisitors
    Follow